Sector: Health Care
Director information for STERIS (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Christopher S. Holland | Former Senior VP & CFO C.R. Bard; Retired, Former Senior VicePresident and Chief FinancialOfficer of C.R. Bard | 59 | ["1","Over thirty years of combined professional experience as a finance executive and investment banker","Experience as the CFO of a publicly traded medical technologies company","Extensive financial experience in the healthcare industry, medical devices and technology"] | ["Audit","Compensation and Organization Development","Audit Committee","Compensation and Organization Development Committee (Chair)"] | 2026 |
| Cynthia L. Feldmann | Retired, Former President & Founder Jetty Lane Associates | 73 | ["1","Retired certified public accountant with 27 years of experience in two large global accounting firms","Founder and President of Jetty Lane Associates","Life Sciences Business Development Officer for Palmer & Dodge, LLP","Partner with KPMG LLP, serving as Partner-in-Charge of National Medical Technologies Practice","Employee at Coopers & Lybrand, named Partner-in-Charge of its Life Sciences practice","Director of Hanger, Inc. from 2003 to 2018","Director of Frequency Therapeutics, Inc. from 2020 to 2023","Director of Alexandria Real Estate Equities, Inc. from 2022 to 2025","Director of UFP Technologies, Inc. since 2017"] | ["Audit","Compensation and Organization Development","Audit Committee","Nominating and Governance Committee (Chair)"] | 2026 |
| Daniel A. Carestio | President and CEO STERIS; President and Chief Executive Officer | 53 | ["Many years of experience in all operating aspects of STERIS's business","Familiarity with healthcare and related industries","Unique perspectives into healthcare and related industries","Oversight of the Company","Direction and strategies"] | ["Nominating and Governance","Compliance and Technology Committee"] | 2026 |
| Dr. Esther M. Alegria | Executive Consultant and Advisor at The LaSalle Group | 67 | ["Over 25 years of experience in successful advancements of vaccines and therapeutic drugs","Founder of APIE Therapeutics","Chief Executive Officer from 2020 to 2023 at APIE Therapeutics","Senior Vice President, Global Manufacturing at Biogen, Inc.","Experience in operational guidance for senior executives at Catalyst Excel & Advance","Director of AVID Bioservices, Inc. from 2021 to 2025","Member of the Board of Trustees for the Puerto Rico Science, Technology and Research Trust"] | ["Audit","Compensation and Organization Development","Compliance and Technology","Compliance and Technology Committee","Nominating and Governance Committee"] | 2026 |
| Dr. Mohsen M. Sohi | Former CEO of Freudenberg SE; Retired, Former Chief Executive Officer at Freudenberg SE | 67 | ["2","CEO of Freudenberg SE","Managing Partner of Freudenberg and Co","President and Chief Executive Officer of Freudenberg-NOK","Senior Vice President at NCR Corporation","President at Honeywell Electronic Materials"] | ["Nominating and Governance Committee"] | 2026 |
| Dr. Nirav R. Shah | Senior Scholar, Stanford University | 54 | ["Experience at leading public health agencies","Service as COO for Clinical Operations of leading healthcare providers","Management experience in the healthcare industry","Experience as a practicing physician","Focus on innovative models in healthcare"] | ["Compliance and Technology","Compensation and Organization Development Committee","Compliance and Technology Committee"] | 2026 |
| Louis A. Shapiro | Retired, Former President and CEO of Hospital for Special Surgery | 66 | ["1","Healthcare industry experience as a CEO of one of the nation’s leading hospitals","Board member and advisor to several healthcare companies","Operational, industry and financial expertise"] | ["Audit","Compensation and Organization Development","Audit Committee","Compliance and Technology Committee"] | 2026 |
| Paul E. Martin | Former Senior V.P. & CIO Baxter International; Retired, Former Senior VicePresident & Chief InformationOfficer of Baxter International | 68 | ["2","former Senior Vice President & Chief Information Officer of Baxter International","extensive professional management experience","technology and security risk experience","financial experience","international experience","life sciences and healthcare experience"] | ["Audit","Compensation and Organization Development","Compliance and Technology","Audit Committee","Compensation and Organization Development Committee"] | 2026 |
| Pierre Boulud | CEO of bioMérieux; Chief Executive Officer | 54 | ["Chief Executive Officer of a European-based biotechnology company","many years of industry experience","extensive leadership experience","global perspective","operational expertise"] | [] | 2026 |
